

Item: 11.2

REPORT CLASSIFICATION	✓	CATEGORY OF PAPER	✓
Official	✓	Proposes specific action	
Official: Sensitive Commercial		Provides assurance	✓
Official: Sensitive Personal		For information only	

BOARD
25 MARCH 2025

Report Title:	Quality and Safety Committee Highlight Report and Confirmed Minutes
----------------------	--

Purpose of report

To provide the Board with a summary of the key points from the meeting of the Quality and Safety Committee held on 11 March 2025 and the confirmed minutes from the 9 January 2025.

Key points

The Committee considered several issues and supporting papers at its meeting held on 11 March 2025 and the key points are summarised below.

- **Quality Report** - The report provided the Committee with oversight of key quality themes, risks and exceptions outlined in the ICB Area Quality reports for the North and South Areas. Updates and assurance were provided on a number of areas including Never Events - a recent never event has been reported the South, this issue had been discussed at quality and oversight meetings. The PSIRF new methodology was being used to investigate these; Healthcare Associated Infection (HCAI) rates continue to be over trajectory for key HCAI infections and plans are in place to address; concerns in relation to clostridium difficile and the impact on flow across Trusts and secondary care; Urgent and Emergency Care (UEC) system pressures and quality concerns relate to use of escalation spaces, waits and handovers with a new quality assurance process being introduced to review the effectiveness and safety of processes in UECs.
- **Special Educational Needs and Disabilities (SEND) Statutory Duties** - The report informed the Committee of the SEND regulatory framework and provided an overview of the ICB's statutory duties. The report gave assurance of the outcomes of the SEND inspections to date.
- **Quarter Three Complaints Report** – The Committee received an update regarding the concerns, issues and complaints received in Quarter Three of 2024/25. The report gave assurance to the committee regarding a robust action plan is in place for both complaint functions to ensure a smooth transition to streamline both ICB and primary care complaints handling processes from 01 April 2025.
- **Terms of Reference (ToR) for Safeguarding Health Executive Group Subcommittee** – The report provided the Committee proposed revisions to the subcommittee ToRs as a result of changes in statutory guidance.
- **Autism** - A patient story highlighted the long waiting times for assessment and management. Whilst reflecting the national situation this continues to be a major concern for parents and affected young people and adults.

Risks and issues

The Committee will continue to receive and review the corporate risks aligned to the quality and safety portfolio to provide assurance to the Board that the quality and safety risks contained within the corporate risk register reflect the current environment.

Assurances and supporting documentation

The Committee received several items for assurance including:

- Patient Safety Centre Update
- Clinical Effectiveness and Governance Subcommittee Highlight Report
- Integrated Delivery Report
- North and South Area Quality and Safety Subcommittee Minutes

Recommendation/action required

The Board is asked to note the key highlights from the meeting held on 11 March 2025 receive the confirmed minutes from the 9 January 2025 meeting for information and assurance.

Acronyms and abbreviations explained

As described in the report.

Sponsor/approving executive director	Sir Pali Hungin, Chair of Quality and Safety Committee and Independent Non Executive Member Hilary Lloyd, Chief Nurse and AHP Officer
Date approved by executive director	18/03/2025
Report author	Rebecca Herron, Corporate Committee Officer

Link to ICP strategy priorities (please tick all that apply)

Longer and Healthier Lives	✓
Fairer Outcomes for All	✓
Better Health and Care Services	✓
Giving Children and Young People the Best Start in Life	✓

Relevant legal/statutory issues

Note any relevant Acts, regulations, national guidelines etc

Any potential/actual conflicts of interest associated with the paper? (please tick)	Yes		No	✓	N/A	
Equality analysis completed (please tick)	Yes		No		N/A	✓
If there is an expected impact on patient outcomes and/or experience, has a quality impact assessment been undertaken? (please tick)	Yes		No		N/A	✓

Essential considerations

Financial implications and considerations	N/A
Contracting and Procurement	N/A

Local Delivery Team	N/A
Digital implications	N/A
Clinical involvement	Clinical representation within the committee
Health inequalities	N/A
Patient and public involvement	The committee receives regular updates concerning patient and public engagement
Partner and/or other stakeholder engagement	N/A
Other resources	N/A